Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Reason for treatment discontinuation for metastatic urothelial carcinoma patients receiving everolimus and pazopanib combination at dose levels 1 and 0 (DL-1 and DL0)
| Reason for discontinuation | Treatment DL-1 (n = 16) N (%) | Treatment DL0 (n = 3) N (%) | Total (n = 19) N (%) |
|---|---|---|---|
| Adverse event/toxicity | — | 1 (33.3) | 1 (5.3) |
| Progressive disease | 14 (87.5) | 1 (33.3) | 15 (78.9) |
| Death | 1 (6.3) | — | 1 (5.3) |
| Physician decision | — | 1 (33.3) | 1 (5.3) |
| Patient withdrawal | 1 (6.3) | — | 1 (5.3) |
